Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 7 October 2016 Three Idylla™ Test Performance Studies to be presented at Esmo Oncology Conference Non-regulated information 21 June 2016 Biocartis launches advanced EGFR Mutation Assay detecting over 50 mutations Important addition to Biocartis’ core oncology menu now covering most known and used oncology biomarkers Non-regulated information 1 June 2016 Idylla™ Ebola Virus Triage Test Granted Emergency Use Authorization by U.S. FDA Non-regulated information 23 May 2016 Study demonstrating Biocartis’ BRAF liquid biopsy assay... Test can predict therapy response over the course of the cancer treatment Non-regulated information 26 April 2016 Biocartis Strengthens Biomarker Portfolio for Colorectal Cancer Exclusive license of recently detected EGFR resistance mutations Non-regulated information 3 February 2016 Biocartis & Amgen Collaborate to Offer Rapid RAS Biomarker Testing to Selected Hospitals and Clinics... Non-regulated information 7 January 2016 Biocartis & Merck to Collaborate on New Liquid Biopsy Technology for RAS Biomarker Testing Non-regulated information 22 December 2015 Biocartis launches world’s first fully automated liquid biopsy assay and its second tissue assay for colorectal cancer Launch of two new tests on its Idylla™ molecular diagnostics platform strengthens the company’s assay menu Non-regulated information 16 December 2015 Biocartis announces financial calendar 2016 Non-regulated information 30 November 2015 Biocartis announces launch of Influenza-Respiratory Virus Panel on the Idylla™ platform Non-regulated information Pagination First page « First Previous page ‹‹ … Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Current page 11 Page 12 Next page ›› Last page Last »